New inhaled drug shows promise for cystic fibrosis in early trial
Disease control
Completed
This study tested a new inhaled medicine called ETD001 in 57 adults with cystic fibrosis. The goal was to see if it is safe and if it can improve lung function. Participants took the drug twice a day for up to 28 days and had their breathing tested. The results will help decide i…
Phase: PHASE2 • Sponsor: Enterprise Therapeutics Ltd • Aim: Disease control
Last updated May 17, 2026 09:22 UTC